Amendments to the Claims

This listing of claims will replace all prior versions, and listings, of claims in the application.

Listing of Claims:

Claim 1. (previously presented) An isolated biopolymer marker consisting of amino acid residues 2-12 of SEQ ID NO:1.

Claims 2-35. (cancelled)

Claim 36. (currently amended) A method for diagnosing myocardial infarction (MI), intracerebral hemorrhage (ICH) or congestive heart failure (CHF) by <u>identifying a mass spectral profile characteristic</u> ~~determining the presence~~ of a biopolymer marker consisting of amino acid residues 2-12 of SEQ ID NO:1 <u>from a mass spectrometric analysis of a sample obtained from a patient</u> comprising:

(a) conducting <u>said</u> mass spectrometric analysis on [[a]] <u>said</u> sample ~~obtained from a patient~~ in a manner effective to maximize analysis of peptide fragments contained therein;

(b) comparing a <u>reference</u> mass spectral profile <u>characteristic</u> of said biopolymer marker consisting of amino acid residues 2-12

2

of SEQ ID NO:1 having an ion peak at about 1348 daltons to mass

spectral profiles of peptides obtained and analyzed from said

sample; and

(c) confirming [[the]] a presence of said mass spectral

profile characteristic of a biopolymer marker consisting of amino

acid residues 2-12 of SEQ ID NO:1 in said mass spectrometric

analysis of a sample obtained from a patient by identifying a mass

spectral profile having an said ion peak at about 1348 daltons;

wherein the presence of said mass spectral profile characteristic

of a biopolymer marker consisting of amino acid residues 2-12 of

SEQ ID NO:1 diagnoses myocardial infarction (MI), intracerebral

hemorrhage (ICH) or congestive heart failure (CHF).

Claim 37. (previously presented) The method of claim 36,

wherein said sample is an unfractionated body fluid or a tissue

sample.

Claim 38. (previously presented) The method of claim 36,

wherein said sample is selected from the group consisting of blood,

blood products, urine, saliva, cerebrospinal fluid, and lymph.

3

Claim 39. (previously presented) The method of claim 36, wherein said mass spectrometric analysis is Surface Enhanced Laser Desorption Ionization (SELDI) mass spectrometry (MS).

Claims 40. (previously presented) The method of claim 36, wherein said patient is a human.

Claim 41. (previously presented) A myocardial infarction (MI), intracerebral hemorrhage (ICH) or congestive heart failure (CHF) diagnostic kit comprising: (a) a peptide consisting of amino acid residues 2-12 of SEQ ID NO:1 and (b) an antibody that binds to said peptide in a sample obtained from a patient.

Claim 42. (previously presented) The myocardial infarction (MI), intracerebral hemorrhage (ICH) or congestive heart failure (CHF) diagnostic kit of claim 41, wherein said antibody is immobilized on a solid support.

Claim 43. (previously presented) The myocardial infarction (MI), intracerebral hemorrhage (ICH) or congestive heart failure (CHF) diagnostic kit of claim 41, wherein said antibody is labeled.